Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir - PubMed (original) (raw)
Clinical Trial
. 2001 Feb 15;183(4):523-31.
doi: 10.1086/318537. Epub 2001 Jan 11.
Affiliations
- PMID: 11170976
- DOI: 10.1086/318537
Clinical Trial
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
L V Gubareva et al. J Infect Dis. 2001.
Abstract
Volunteers experimentally infected with influenza A/Texas/36/91 (H1N1) virus and treated with the neuraminidase (NA) inhibitor oseltamivir were monitored for the emergence of drug-resistant variants. Two (4%) of 54 resistant viruses were detected by NA inhibition assay among last-day isolates recovered from 54 drug recipients. They bore a substitution His274Tyr in the NA. Hemagglutinin (HA) variants detected in the placebo group differed from the egg-adapted inoculum virus by virtue of amino acid substitutions at residues 137, 225, or both. These variants had a higher affinity for Neu5Ac(alpha2-6)Gal-containing receptors, which are characteristic of human respiratory epithelium, than for Neu5Ac(alpha2-3)Gal-containing receptors, which are typical of chicken egg allantoic membrane. Although appearing to be more sensitive to oseltamivir in humans, the variants with increased affinity for Neu5Ac(alpha2-6)Gal receptors were less sensitive than the Neu5Ac(alpha2-3)Gal-binding variants in Madin-Darby canine kidney cells. Thus, HA affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans.
Similar articles
- Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene.
Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, Tisdale M, Boivin G. Abed Y, et al. J Infect Dis. 2002 Oct 15;186(8):1074-80. doi: 10.1086/344237. Epub 2002 Sep 30. J Infect Dis. 2002. PMID: 12355356 - Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells.
Govorkova EA, Matrosovich MN, Tuzikov AB, Bovin NV, Gerdil C, Fanget B, Webster RG. Govorkova EA, et al. Virology. 1999 Sep 15;262(1):31-8. doi: 10.1006/viro.1999.9892. Virology. 1999. PMID: 10489338 - Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV. Gubareva LV. Virus Res. 2004 Jul;103(1-2):199-203. doi: 10.1016/j.virusres.2004.02.034. Virus Res. 2004. PMID: 15163510 - Influenza virus susceptibility and resistance to oseltamivir.
Aoki FY, Boivin G, Roberts N. Aoki FY, et al. Antivir Ther. 2007;12(4 Pt B):603-16. Antivir Ther. 2007. PMID: 17944268 Review. - Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.
Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Ison MG, et al. J Infect Dis. 2006 Mar 15;193(6):760-4. doi: 10.1086/500465. Epub 2006 Feb 13. J Infect Dis. 2006. PMID: 16479508 Review.
Cited by
- Evolutionary Insights from Association Rule Mining of Co-Occurring Mutations in Influenza Hemagglutinin and Neuraminidase.
Galeone V, Lee C, Monaghan MT, Bauer DC, Wilson LOW. Galeone V, et al. Viruses. 2024 Sep 25;16(10):1515. doi: 10.3390/v16101515. Viruses. 2024. PMID: 39459850 Free PMC article. - Influenza A virus within-host evolution and positive selection in a densely sampled household cohort over three seasons.
Bendall EE, Zhu Y, Fitzsimmons WJ, Rolfes M, Mellis A, Halasa N, Martin ET, Grijalva CG, Talbot HK, Lauring AS. Bendall EE, et al. Virus Evol. 2024 Oct 3;10(1):veae084. doi: 10.1093/ve/veae084. eCollection 2024. Virus Evol. 2024. PMID: 39444487 Free PMC article. - Influenza A virus within-host evolution and positive selection in a densely sampled household cohort over three seasons.
Bendall EE, Zhu Y, Fitzsimmons WJ, Rolfes M, Mellis A, Halasa N, Martin ET, Grijalva CG, Talbot HK, Lauring AS. Bendall EE, et al. bioRxiv [Preprint]. 2024 Aug 19:2024.08.15.608152. doi: 10.1101/2024.08.15.608152. bioRxiv. 2024. PMID: 39229225 Free PMC article. Updated. Preprint. - Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism.
Liu HY, Li Z, Reindl T, He Z, Qiu X, Golden RP, Donovan KA, Bailey A, Fischer ES, Zhang T, Gray NS, Yang PL. Liu HY, et al. Nat Commun. 2024 Jun 19;15(1):5179. doi: 10.1038/s41467-024-49161-9. Nat Commun. 2024. PMID: 38898037 Free PMC article. - Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy.
Batool S, Chokkakula S, Song MS. Batool S, et al. Microorganisms. 2023 Jan 11;11(1):183. doi: 10.3390/microorganisms11010183. Microorganisms. 2023. PMID: 36677475 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical